WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/005281    International Application No.:    PCT/EP2003/007198
Publication Date: 15.01.2004 International Filing Date: 04.07.2003
Chapter 2 Demand Filed:    19.01.2004    
C07D 401/14 (2006.01), C07D 405/14 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4002 Basel (CH) (AE, AG, AL, AM, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MC, MD, MK, MN, MX, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SY, TJ, TM, TN, TR, TT, UA, UZ, VC, VN, YU, ZA, ZW only).
NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT) (AT only).
BREITENSTEIN, Werner [CH/CH]; (CH) (For US Only).
FURET, Pascal [FR/FR]; (FR) (For US Only).
JACOB, Sandra [AU/FR]; (FR) (For US Only).
MANLEY, Paul, William [GB/CH]; (CH) (For US Only)
Inventors: BREITENSTEIN, Werner; (CH).
FURET, Pascal; (FR).
JACOB, Sandra; (FR).
MANLEY, Paul, William; (CH)
Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH)
Priority Data:
0215676.8 05.07.2002 GB
0229893.3 20.12.2002 GB
Abstract: front page image
(EN)The invention relates to compounds of formula (I) Wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such disease.
(FR)L'invention porte sur des composés de formule (I) dans laquelle les substituants R1, R2 et R4 sont tels qu'indiqués et explicités dans le descriptif, sur des procédés de préparation de ces composés, sur des compositions pharmaceutiques les contenant, sur leur utilisation éventuellement en combinaison avec un ou d'autres composés actifs d'un point de vue pharmaceutique dans le traitement d'une maladie réagissant à l'inhibition de l'activité de la protéine kinase, en particulier une maladie néoplasique telle que la leucémie, et sur un procédé de traitement de cette maladie.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
Publication Language: English (EN)
Filing Language: English (EN)